Immunology Explorer #
The autoimmune and inflammation (I&I) drug landscape. Like oncology it fragments across indications and mechanisms with no single efficacy yardstick, so this is an explorer: filter by target mechanism, modality, route, indication, sponsor, and development stage.
29
I&I assets tracked
18
approved
10
filed or Phase 3
21
distinct mechanisms
14
indications
Filters #
Pick any combination. Within a facet, chips are OR'd; across facets they are AND'd. State is saved in the URL hash so a filtered view is shareable.
of 29 assets shown
Landscape by mechanism #
Competitive density per target mechanism. Rows are ordered by how crowded the mechanism is - the IL-23 and TL1A rows show where the field is concentrating.
| Mechanism | Approved | Filed | Phase 3 | Phase 2 |
|---|---|---|---|---|
| IL-23 p19 |
| - | - | - |
| TL1A | - | - |
|
|
| FcRn |
| - | - | - |
| IL-13 |
| - |
| - |
| IL-17A |
| - | - | - |
| TYK2 |
| - |
| - |
| BAFF/APRIL | - | - |
| - |
| CD19 x FcgRIIb | - | - |
| - |
| IL-12/23 p40 |
| - | - | - |
| IL-17A/F |
| - | - | - |
| IL-23R | - | - |
| - |
| IL-31RA |
| - | - | - |
| IL-4Ralpha |
| - | - | - |
| IL-5 | - |
| - | - |
| JAK1 |
| - | - | - |
| JAK3/TEC |
| - | - | - |
| OX40 | - | - |
| - |
| OX40L | - | - |
| - |
| S1P modulator |
| - | - | - |
| TNF-alpha |
| - | - | - |
| TSLP |
| - | - | - |
Assets #
One row per molecule in its lead indication. Click any column header to sort. A molecule with several approved indications is shown in its most representative one.
| Drug | Sponsor | Mechanism | Modality | Route | Lead indication | Status | Trial |
|---|---|---|---|---|---|---|---|
| Adalimumab (Humira) | AbbVie | TNF-alpha | Monoclonal antibody | SC | Rheumatoid arthritis | approved | OPERA |
| Bimekizumab (Bimzelx)UCB4940 | UCB | IL-17A/F | Monoclonal antibody | SC | Psoriasis | approved | A Study to Evaluate the Efficacy and Safety of B |
| Deucravacitinib (Sotyktu)BMS-986165 | Bristol Myers Squibb | TYK2 | Small molecule | Oral | Psoriasis | approved | POETYK-PSO-3 |
| Dupilumab (Dupixent)REGN668 | Sanofi / Regeneron | IL-4Ralpha | Monoclonal antibody | SC | Atopic dermatitis | approved | Dupilumab in Japanese Patients With Atopic Derma |
| Efgartigimod (Vyvgart)ARGX-113 | argenx | FcRn | Antibody fragment | IV/SC | Myasthenia gravis | approved | Efgartigimod in IVIG Dependent Myasthenia Gravis |
| Etrasimod (Velsipity)APD334 | Pfizer | S1P modulator | Small molecule | Oral | Ulcerative colitis | approved | A Phase 3 Study of Etrasimod in Subjects With Mo |
| Guselkumab (Tremfya)CNTO-1959 | Johnson & Johnson | IL-23 p19 | Monoclonal antibody | SC | Ulcerative colitis | approved | TRILOGY |
| Ixekizumab (Taltz)LY2439821 | Eli Lilly | IL-17A | Monoclonal antibody | SC | Psoriasis | approved | UNCOVER-A |
| Lebrikizumab (Ebglyss) | Eli Lilly | IL-13 | Monoclonal antibody | SC | Atopic dermatitis | approved | LUMINE |
| Mirikizumab (Omvoh)LY3074828 | Eli Lilly | IL-23 p19 | Monoclonal antibody | SC | Ulcerative colitis | approved | LUCENT-URGE |
| Nemolizumab (Nemluvio) | Galderma | IL-31RA | Monoclonal antibody | SC | Prurigo nodularis | approved | A Study to Evaluate the Durability of Response a |
| Nipocalimab (Imaavy)M281 | Johnson & Johnson | FcRn | Monoclonal antibody | IV | Myasthenia gravis | approved | A Study of Nipocalimab in Children Aged 2 to Les |
| Risankizumab (Skyrizi)ABBV-066 | AbbVie | IL-23 p19 | Monoclonal antibody | SC | Psoriasis | approved | IMMprint |
| Ritlecitinib (Litfulo)PF-06651600 | Pfizer | JAK3/TEC | Small molecule | Oral | Alopecia areata | approved | B7981028 |
| Secukinumab (Cosentyx) | Novartis | IL-17A | Monoclonal antibody | SC | Psoriatic arthritis | approved | FUTURE 4 |
| Tezepelumab (Tezspire)AMG-157 | Amgen / AstraZeneca | TSLP | Monoclonal antibody | SC | Severe asthma | approved | NAVIGATOR |
| Upadacitinib (Rinvoq)ABT-494 | AbbVie | JAK1 | Small molecule | Oral | Atopic dermatitis | approved | Open-Label Extension Study of Upadacitinib in Ad |
| Ustekinumab (Stelara) | Johnson & Johnson | IL-12/23 p40 | Monoclonal antibody | SC | Crohn's disease | approved | A Study to Evaluate the Safety and Efficacy of U |
| DepemokimabGSK3511294 | GSK | IL-5 | Monoclonal antibody | SC | Severe asthma | filed | NIMBLE |
| AmlitelimabSAR445229 | Sanofi | OX40L | Monoclonal antibody | SC | Atopic dermatitis | phase 3 | ESTUARY |
| CendakimabABBV-CLS-579? CC-93538 | Bristol Myers Squibb | IL-13 | Monoclonal antibody | SC | Eosinophilic esophagitis | phase 3 | Safety Study of CC-93538 in Adult and Adolescent |
| DuvakitugTEV-48574 | Teva / Sanofi | TL1A | Monoclonal antibody | SC | Inflammatory bowel disease | phase 3 | SUNSCAPE-1 |
| IcotrokinraJNJ-77242113 | Johnson & Johnson | IL-23R | Oral peptide | Oral | Psoriasis | phase 3 | ICONIC-LEAD |
| ObexelimabXmAb5871 | Zenas BioPharma | CD19 x FcgRIIb | Monoclonal antibody | SC | IgG4-related disease | phase 3 | INDIGO |
| PovetaciceptALPN-303 | Vertex Pharmaceuticals | BAFF/APRIL | Fc fusion | SC | IgA nephropathy | phase 3 | OLYMPUS |
| RocatinlimabAMG-451 | Amgen / Kyowa Kirin | OX40 | Monoclonal antibody | SC | Atopic dermatitis | phase 3 | ROCKET-Horizon |
| TulisokibartMK-7240 | Merck | TL1A | Monoclonal antibody | SC | Ulcerative colitis | phase 3 | A Study to Evaluate Efficacy and Safety of Tulis |
| ZasocitinibTAK-279 | Takeda | TYK2 | Small molecule | Oral | Psoriasis | phase 3 | TAK-279 vs deucravacitinib Ph3 |
| AfimkibartRG6631 | Roche | TL1A | Monoclonal antibody | SC | Inflammatory bowel disease | phase 2 | SIBERITE-PEDS |